Challenges and Opportunities for Pancreatic Cancer...
Pancreatic ductal adenocarcinoma (PDAC) is among the most immune-resistant tumor types. ... Cited by: 9  Author: Adham S. Bear, Robert H. Vonderheide, ...
Publish Year: 2020

Pancreatic cancer: challenges and opportunities | BMC ...
Nov 22, 2018 - We briefly introduce the most groundbreaking advances in pancreatic cancer diagnosis and clinical treatment strategies over the past 15 years, including surgery, chemotherapy, endoscopic... Cited by: 23  Author: Huyan Zhu, Yue Li, Yiqi Du, Min Li
Publish Year: 2018

New Strategies in Pancreatic Cancer: Emerging ...
https://cancerres.aacrjournals.org/content/16/17/4313
Sep 01, 2019 - Background. Pancreatic cancer (PC) is the fourth leading cause of cancer-related death for both men and women in the United States. It is one of the most lethal malignancies, with a 5-year... Cited by: 73  Author: Donghui Li, James L. Abbruzzese
Publish Year: 2010

Challenges and Opportunities for Pancreatic Cancer...
Current and Emerging Therapies in Metastatic Pancreatic Cancer
https://clincancerres.aacrjournals.org/content/23/7/1670
Apr 01, 2017 · Gemcitabine. Studies aiming to improve pancreatic cancer therapy are almost always conducted in the metastatic setting. From a historical perspective, gemcitabine was the first agent approved by the FDA for the treatment of pancreatic cancer and was approved based on an improvement in clinical benefit.
Cited by: 85   Author: Gulam Abbas Manjil, Kenneth P. Olive, Yvon...
Publish Year: 2017   Estimated Reading Time: 10 mins

Pancreatic cancer: challenges and opportunities | BMC ...
Nov 22, 2018 · Pancreatic cancer is the fourth leading cause of cancer-related death in the United States, with increasing incidence. The mortality rate of pancreatic cancer is rising rapidly, and is projected to be the second most common of all malignant tumors by 2030. However, the diagnosis and therapy of pancreatic cancer remain a formidable challenge.
Cited by: 39   Author: Huiyun Zhu, Tuo Li, Yiqi Du, Min Li
Publish Year: 2018   Estimated Reading Time: 8 mins

PEOPLE ALSO ASK
What are the advances in pancreatic cancer treatment?

Are there any clinical trials for pancreatic cancer?
Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities

Abstract
Pancreatic carcinoma is one of the leading causes of cancer-related death worldwide. Despite early detection and advances in therapeutics, the prognosis remains dismal. The outcomes and therapeutic approach are dependent on the stage of pancreatic carcinoma at the time of diagnosis. The standard of care is surgery followed by adjuvant chemotherapy. The advent of newer drugs has changed the landscape of adjuvant therapy. Moreover, recent trials have highlighted the role of neoadjuvant chemotherapy and clinical outcomes for resection and long-term survival. In conclusion, the continuous research and advancements in this field will play a crucial role in improving outcomes for patients with pancreatic carcinoma.
Current and emerging therapeutic strategies in pancreatic cancer: current and emerging therapies in metastatic pancreatic ... https://www.nature.com/articles/s41575-018-0005-x
May 01, 2018 · Challenges include identification of at-risk populations for screening and prevention, early detection by advanced imaging and novel cancer (bio)markers and most notably better therapeutic options...
Cited by: 344 · Author: John P. Neoptolemos, Jörg Klee, Jörg Ki...
Publish Year: 2018

Current and Emerging Therapies in Metastatic Pancreatic ... https://clincancerres.aacrjournals.org/content/23/7/1670
Apr 01, 2017 · Gemcitabine. Studies aiming to improve pancreatic cancer therapy are almost always conducted in the metastatic setting. From a historical perspective, gemcitabine was the first agent approved by the FDA for the treatment of pancreatic cancer and was approved based on an improvement in clinical benefit.
Cited by: 85 · Author: Gulam Abbas Manji, Kenneth P. Olive, Yv...
Publish Year: 2017 · Estimated Reading Time: 10 mins

Nov 22, 2018 · Pancreatic cancer is the fourth leading cause of cancer-related death in the United States, with increasing incidence. The mortality rate of pancreatic cancer is rising rapidly, and is projected to be the second most common of all malignant tumors by 2030. However, the diagnosis and